• Manisha
• Ravikant Gupta

The present study was carried out to develop sustained release matrix tablets of mosapride citrate dihydrate. Matrix tablets of mosapride citrate dihydrate with two different viscosity grades of hydroxypropyl methylcellulose were prepared by dry granulation and direct compression method and evaluated. The study demonstrated that combination of HPMC K4M and HPMC mosapride citrate dihydrate. This can be expected to reduce the frequency of administration and decrease the dose – dependent side effects associated with repeated administration of conventional mosapride citrate dihydrate tablets. The cumulative drug release of innovators brand (MOZA SR, Intas Pharmaceuticals) of sustained release tablet of mosapride citrate dihydrate were compaired for in vitro dissolution study. Hence it can be concluded that once daily sustain release matrix tablet of mosapride citrate dihydrate having short half life, was found to exert a satisfactory sustained release profile which may provide an improved bioavailability, increased therapeutic efficacy and patient compliance.

Matrix Tablet, Sustained release

"TO FORMULATE AND EVALUATE SUSTAINED RELEASE MATRIX TABLETS OF MOSAPRIDE CITRATE DIHYDRATE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 5, page no.k393-k423, May-2022, Available :http://www.jetir.org/papers/JETIR2205B54.pdf

"TO FORMULATE AND EVALUATE SUSTAINED RELEASE MATRIX TABLETS OF MOSAPRIDE CITRATE DIHYDRATE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 5, page no. ppk393-k423, May-2022, Available at : http://www.jetir.org/papers/JETIR2205B54.pdf